Rifampicin-induced thrombocytopenia

Hadfield, Jane

doi:10.1136/pgmj.56.651.59

Cited by 27 publications

(12 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hematologic monitoring may be done periodically in patients on long-term, intermittent therapy, particularly during initiation of therapy in patients who have previously received rifampin, as severe thrombocytopenia has been demonstrated in patients with gaps in therapy. 67 In patients with rifampin-associated thrombocytopenia on intermittent therapy, a switch to daily therapy may also be considered. 68…”

Section: Rifampinmentioning

confidence: 99%

See 1 more Smart Citation

Antimicrobial Drug-Induced Thrombocytopenia: A Review of the Literature

Loo

Gerzenshtein

Ison

2012

Semin Thromb Hemost

View full text Add to dashboard Cite

The incidence of drug-induced thrombocytopenia (DIT) is not well-defined, but is estimated to occur at a minimum of 10 cases per million per year. This review will focus on the potential DIT associated with specific antibacterial, antifungal, antiviral, and antiparasitic agents. Case reports, cohort studies, and clinical trials were identified using PubMed search terms for each antimicrobial along with the Boolean combiner AND to match with the following outcomes: thrombocytopenia and bleed. Thrombocytopenia was defined as a platelet count of < 100 × 10(9)/L or a decrease in platelet count of at least 50% from baseline. A majority of the data supporting antimicrobial-induced thrombocytopenia consist of case reports and small studies. However, clinicians should be vigilant in monitoring patient platelet counts, as an immune-mediated mechanism is frequently responsible for this hematologic adverse effect and is therefore unpredictable.

show abstract

Section: Rifampinmentioning

confidence: 99%

“…Rifampin [58][59][60][61][62][63][64][65]67,68 Case reports and case series, but overall, rare. Possibly associated with high-dose, intermittent treatment rather than lower-dose daily therapy.…”

Section: Rifamycinmentioning

confidence: 99%

Antimicrobial Drug-Induced Thrombocytopenia: A Review of the Literature

Loo

Gerzenshtein

Ison

2012

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…These antibodies fi x a complement on the blood platelets in the presence of rifampin resulting in platelet destruction [27]. Other studies by Rieg et al, and Torre et al [28,29],…”

Section: Discussionmentioning

confidence: 93%

Effects of Duration of Treatment, HIV and HCV Co-Infection on Hematological and Hepatic Functions in Libyan Patients with Pulmonary Tuberculosis

M¹

2018

Int J Pharm Sci Dev Res

View full text Add to dashboard Cite

Background: Pulmonary tuberculosis (TB) remains a major global health problem despite the availability of effi cient treatment over the last decades. TB is the most common opportunistic infection among HIV patients and complicated the outcome of treatment globally. Aims: The prevalence of HCV infection among TB patients has not fully been investigated and limited data on rates of HCV co-infection in TB patients exist. Therefore, this study was aimed to investigate the effects of duration of treatment with fi rst line anti-TB drug, HIV, HCV and co-infection on haematological and hepatic functions in Libyan patients with pulmonary TB. Methods: A total of 120 Libyan newly diagnosed pulmonary TB patients (74 males and 46 females) with age range of 26 to 41 years old were enrolled in this study. They were selected for a regular follow up on the basis of inclusion and exclusion criteria. Pulmonary TB was confi rmed by chest X-ray and sputum smear in all the patients. Patients were divided into three groups; the fi rst group of 75 patients with no HIV and HCV infections (positive control), the second group of 35 patients who had TB and HIV co-infection, before starting anti-microbial therapy, while the third group consists of 20 patients who had TB and HCV coinfection before starting anti-HCV treatment. All patients received a confi rmation of the 1st line anti-TB drug (isoniazid, rifampin, ethambutol and pyrazinamide for fi ve consecutive weeks) simultaneously. Results: The results showed a signifi cant decrease in white blood cells (WBCs) in all the groups of patients and signifi cant changes in other haematological parameters, there were also signifi cant increases in the hepatic enzyme activities, alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (ALP), in all the groups which indicate hepatic toxicity. Conclusion: Treatment with fi rst line anti-TB drug simultaneously produced hepatotoxicity after two weeks which is more in HIV and HCV co-infection patients.

show abstract

“…This finding correlates with previous studies reporting that intermittent drug administration is likely to result in a more severe and rapid adverse reaction. RFP-induced thrombocytopenia mostly developed in patients who were either on intermittent-dose regimens or were re-administered RFP after an interval (5,7,9,10).…”

Section: Discussionmentioning

confidence: 99%